Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.

Feldmann M., Maini RN., Woody JN., Holgate ST., Winter G., Rowland M., Richards D., Hussell T.

DOI

10.1016/S0140-6736(20)30858-8

Type

Journal article

Publication Date

2020-05-02T00:00:00+00:00

Volume

395

Pages

1407 - 1409

Total pages

2

Keywords

Antibodies, Betacoronavirus, COVID-19, Clinical Trials as Topic, Coronavirus Infections, Cytokines, Humans, Inflammation, Pandemics, Pneumonia, Viral, SARS-CoV-2, Tumor Necrosis Factor-alpha, COVID-19 Drug Treatment

Permalink More information Close